Amundson Adam W, Johnson Rebecca L, Abdel Matthew P, Mantilla Carlos B, Panchamia Jason K, Taunton Michael J, Kralovec Michael E, Hebl James R, Schroeder Darrell R, Pagnano Mark W, Kopp Sandra L
From the Department of Anesthesiology (A.W.A., R.L.J., C.B.M., J.K.P., J.R.H., S.L.K.), Department of Orthopedics (M.P.A., M.J.T., M.E.K., M.W.P.), and Division of Biomedical Statistics and Informatics (D.R.S.), Mayo Clinic, Rochester, Minnesota.
Anesthesiology. 2017 Jun;126(6):1139-1150. doi: 10.1097/ALN.0000000000001586.
Multimodal analgesia is standard practice for total knee arthroplasty; however, the role of regional techniques in improved perioperative outcomes remains unknown. The authors hypothesized that peripheral nerve blockade would result in lower pain scores and opioid consumption than two competing periarticular injection solutions.
This three-arm, nonblinded trial randomized 165 adults undergoing unilateral primary total knee arthroplasty to receive (1) femoral catheter plus sciatic nerve blocks, (2) ropivacaine-based periarticular injection, or (3) liposomal bupivacaine-based periarticular injection. Primary outcome was maximal pain during postoperative day 1 (0 to 10, numerical pain rating scale) in intention-to-treat analysis. Additional outcomes included pain scores and opioid consumption for postoperative days 0 to 2 and 3 months.
One hundred fifty-seven study patients received peripheral nerve block (n = 50), ropivacaine (n = 55), or liposomal bupivacaine (n = 52) and reported median maximal pain scores on postoperative day 1 of 3, 4, and 4.5 and on postoperative day 0 of 1, 4, and 5, respectively (average pain scores for postoperative day 0: 0.6, 1.7, and 2.4 and postoperative day 1: 2.5, 3.5, and 3.7). Postoperative day 1 median maximal pain scores were significantly lower for peripheral nerve blockade compared to liposomal bupivacaine-based periarticular injection (P = 0.016; Hodges-Lehmann median difference [95% CI] = -1 [-2 to 0]). After postanesthesia care unit discharge, postoperative day 0 median maximal and average pain scores were significantly lower for peripheral nerve block compared to both periarticular injections (ropivacaine: maximal -2 [-3 to -1]; P < 0.001; average -0.8 [-1.3 to -0.2]; P = 0.003; and liposomal bupivacaine: maximal -3 [-4 to -2]; P < 0.001; average -1.4 [-2.0 to -0.8]; P < 0.001).
Ropivacaine-based periarticular injections provide pain control comparable on postoperative days 1 and 2 to a femoral catheter and single-injection sciatic nerve block. This study did not demonstrate an advantage of liposomal bupivacaine over ropivacaine in periarticular injections for total knee arthroplasty.
多模式镇痛是全膝关节置换术的标准做法;然而,区域技术在改善围手术期结局中的作用仍不明确。作者推测,与两种竞争性的关节周围注射溶液相比,外周神经阻滞将导致更低的疼痛评分和阿片类药物消耗量。
这项三臂、非盲试验将165例接受单侧初次全膝关节置换术的成年人随机分为三组,分别接受:(1)股动脉导管加坐骨神经阻滞;(2)罗哌卡因关节周围注射;(3)脂质体布比卡因关节周围注射。意向性分析的主要结局是术后第1天的最大疼痛程度(0至10分,数字疼痛评分量表)。其他结局包括术后第0至2天和3个月的疼痛评分及阿片类药物消耗量。
157例研究患者接受了外周神经阻滞(n = 50)、罗哌卡因(n = 55)或脂质体布比卡因(n = 52)治疗,术后第1天的最大疼痛评分中位数分别为3分、4分和4.5分,术后第0天分别为1分、4分和5分(术后第0天的平均疼痛评分:0.6分、1.7分和2.4分;术后第1天:2.5分、3.5分和3.7分)。与脂质体布比卡因关节周围注射相比,外周神经阻滞术后第1天的最大疼痛评分中位数显著更低(P = 0.016;霍奇斯-莱曼中位数差异[95%CI] = -1[-2至0])。在麻醉后护理单元出院后,与两种关节周围注射相比,外周神经阻滞术后第0天的最大和平均疼痛评分中位数显著更低(罗哌卡因:最大疼痛评分 -2[-3至-1];P < 0.001;平均疼痛评分 -0.8[-1.3至-0.2];P = 0.003;脂质体布比卡因:最大疼痛评分 -3[-4至-2];P < 0.001;平均疼痛评分 -1.4[-2.0至-0.8];P < 0.001)。
基于罗哌卡因的关节周围注射在术后第1天和第2天提供的疼痛控制与股动脉导管和单次注射坐骨神经阻滞相当。本研究未证明脂质体布比卡因在全膝关节置换术的关节周围注射中优于罗哌卡因。